RSV guidance widens antibody protection for at-risk toddlers

Updated American Academy of Pediatrics advice expands eligibility for some one-year-olds entering a second RSV season, as doctors stress the importance of timely protection.

Pediatricians are describing the respiratory syncytial virus, or RSV, shot as a significant advance in protecting young children, as new guidance broadens the number of toddlers who may qualify for immunisation in their second RSV season. The change reflects growing concern about a virus that can cause serious breathing problems in infants and remains one of the most common reasons for hospital care in the youngest children.

According to the American Academy of Pediatrics, updated advice now covers more one-year-olds who are considered at increased risk, widening access to the RSV antibody shot for children who might previously have been left unprotected. The academy says the aim is to extend defence through another season, when young children can still face meaningful exposure and illness.

The CDC says RSV vaccines and antibody products are part of a wider prevention strategy designed to reduce severe disease in infants, older adults and pregnant women. Its vaccine guidance says the available products are monitored through safety systems and are recommended according to age and clinical risk, with the goal of preventing the most serious outcomes rather than eliminating every infection.

For families and paediatric practices, the practical message is that timing matters. The American Academy of Pediatrics advises that eligible infants and children should receive protection before the virus begins to circulate widely, and it also encourages practices to use reminder systems so children do not miss the narrow window when the benefit is greatest. For doctors who have watched RSV fill wards each winter, that makes the shot, in their view, less of an incremental step than a real shift in prevention.